Showing 5461-5470 of 9561 results for "".
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- FDA Grants Breakthrough Status for Baricitinib in AAhttps://practicaldermatology.com/news/fda-grants-breakthrough-status-for-baricitinib-in-alopecia-1/2460308/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Eli Lilly and Company and Incyte Corporation’s baricitinib for the treatment of alopecia areata (AA). Baricitinib is currently approved for the treatment of adults with moderately to severe
- AMA: New CPT Code to Report Novel Coronavirus Testhttps://practicaldermatology.com/news/ama-new-cpt-code-to-report-novel-coronavirus-test/2460307/The Current Procedural Terminology (CPT®)Editorial Panel has approved a new addition to the CPT code set to report testing for the virus that causes COVID-19. The American Medical Association (AMA) says the code will help streamline data-driven resource and allocation planning in t
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is
- Study: Mohs Scars from Facial Skin Cancers Longer than Patients Expecthttps://practicaldermatology.com/news/study-mohs-scars-from-facial-skin-cancers-longer-than-patients-expect/2460301/Scars from Mohs micrographic surgery for facial skin cancers may be longer than patients expect, according to new research published in JAMA Network Open. In this cross-sectional study of 1
- Study: DermTech’s Non-Invasive Gene Expression Testing Improves Early Melanoma Detectionhttps://practicaldermatology.com/news/study-dermtechs-non-invasive-gene-expression-testing-improves-early-melanoma-detection/2460297/A large registry study confirms that DermTech Pigmented Lesion Assay can reduce unnecessary biopsies by up to 90 percent, lower healthcare costs, and rule out melanoma. “The DermTech PLA helps clinicians employ precision dermatology and harness genomics technology to detect malign
- BTL Files Suit Against Allergan, Alleges Misleading Advertisinghttps://practicaldermatology.com/news/btl-files-suit-against-allergan-alleges-misleading-advertising/2460288/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Business News: Lilly, Dermira Acquisition Completehttps://practicaldermatology.com/news/business-news-lilly-dermira-acquisition-complete/2460287/Eli Lilly and Company has completed its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 that is being evaluated in a Phase 3 clinical development
- Sun Pharma Survey: Impact of Psoriasis on Patients is Extensivehttps://practicaldermatology.com/news/sun-pharma-survey-impact-of-psoriasis-on-patients-is-extensive/2460284/The impact of moderate-to-severe plaque psoriasis on social and personal interactions can be extensive, results of a new survey from Sun Pharma confirm. In fact, 44 percent of respondents said that they often or sometimes feel humiliated by the appearance of psoriasis. More than a quarter (28 per